Table 1.
Characteristics of patients (N = 270).
| Variables | Values |
|---|---|
| At diagnosis | |
| Demographic data | |
| Age (years) | 61.0 (50.0–69.3) |
| Male sex (N, (%)) | 93 (34.4) |
| Female sex (N, (%)) | 177 (66.6) |
| BMI (kg/m2) | 22.4 (20.2–24.5) |
| Smoking history (N, (%)) | 9 (3.3) |
| AAV Subtypes (N, (%)) | |
| MPA | 152 (56.3) |
| GPA | 66 (24.4) |
| EGPA | 52 (19.3) |
| ANCA positivity (N, (%)) | |
| MPO-ANCA (or P-ANCA) positivity | 191 (70.7) |
| PR3-ANCA (or C-ANCA) positivity | 41 (15.2) |
| AAV-specific indices | |
| BVAS | 12.0 (7.0–18.0) |
| FFS | 1.0 (0–2.0) |
| Acute-phase proteins | |
| ESR (mm/h) | 60.5 (22.0–96.0) |
| CRP (mg/L) | 13.8 (1.6–68.9) |
| Comorbidities at diagnosis (N, (%)) | |
| Type 2 diabetes mellitus | 72 (26.7) |
| Arterial hypertension | 110 (40.7) |
| Hyperlipidaemia | 55 (20.4) |
| ANI-related variables | |
| MCV (fL) | 90.4 (87.5–93.9) |
| Adjusted MCV * (fL) | 92.0 (92.0–93.9) |
| AST (IU/L) | 18.0 (15.0–24.0) |
| ALT (IU/L) | 16.0 (11.0–25.0) |
| AST/ALT | 1.2 (0.9–1.6) |
| Adjusted AST/ALT ** | 1.2 (0.9–1.6) |
| BMI (kg/m2) | 22.4 (20.2–24.5) |
| Male sex | 93 (34.4) |
| ANI | −1.15 (−3.89–1.55) |
| During follow-up | |
| All-cause mortality | |
| All-cause mortality (N, (%)) | 32 (11.9) |
| Follow-up duration based on all-cause mortality (months) | 47.8 (15.7–82.1) |
| Medications administered during follow-up (N, (%)) | |
| Glucocorticoid | 254 (94.1) |
| Cyclophosphamide | 153 (56.7) |
| Rituximab | 45 (16.7) |
| Azathioprine | 146 (54.1) |
| Mycophenolate mofetil | 51 (18.9) |
| Tacrolimus | 23 (8.5) |
| Methotrexate | 23 (8.5) |
Values are expressed as a median (25~75 percentiles) or a number (percentage). * Adjusted MCV: The range of MCV as a variable for ALI is 92 to 103. Therefore, MCV below 92 is set at 92, and MCV above 103 is set at 103. ** Adjusted AST/ALT: The range of AST/ALT as a parameter of ALI cannot exceed 3. Therefore, AST/ALT above 3 is set at 3. AAV: ANCA-associated vasculitis; ANCA: antineutrophil cytoplasmic antibody; BMI: body mass index; MPA: microscopic polyangiitis; GPA: granulomatosis with polyangiitis; EGPA: eosinophilic GPA; MPO: myeloperoxidase; P: perinuclear; PR3: proteinase 3; C: cytoplasmic; BVAS: Birmingham Vasculitis Activity Score; FFS: Five-Factor Score; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; ANI: the alcoholic liver disease/nonalcoholic fatty liver disease index; MCV: mean corpuscular volume; AST: aspartate aminotransferase; ALT: alanine aminotransferase.